Bingru Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Bingru Liu has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Ayijiang Taledaohan
Department of Medicinal Chemistry, College of Pharmaceutical Sciences of Capital Medical University, Beijing 100069, China
1 shared publication - Qingyan Li
Civil Aviation Medical Center, Civil Aviation Administration of China, Beijing 100123, China
1 shared publication - Shi Qiao
Civil Aviation Medical Center, Civil Aviation Administration of China, Beijing 100123, China
1 shared publication - Yu Lu
Department of Medicinal Chemistry, College of Pharmaceutical Sciences of Capital Medical University, Beijing 100069, China
1 shared publication - Yuji Wang
Department of Medicinal Chemistry, College of Pharmaceutical Sciences of Capital Medical University, Beijing 100069, China
1 shared publication
Latest Publications
- Open Access
The Promoting Role of HK II in Tumor Development and the Research Progress of Its Inhibitors
Increased glycolysis is a key characteristic of malignant cells that contributes to their high proliferation rates and ability to develop drug resistance. The glycolysis rate-limiting enzyme hexokinase II (HK II) is overexpressed in most tumor cells and significantly affects tumor development. This paper examines the structure of HK II and the specific biological factors that influence its role in tumor development, as well as the potential of HK II inhibitors in antitumor therapy. Furthermore, we identify and discuss the inhibitors of HK II that have been reported in the literature.
Open AccessThe Promoting Role of HK II in Tumor Development and the Research Progress of Its Inhibitors
Increased glycolysis is a key characteristic of malignant cells that contributes to their high proliferation rates and ability to develop drug resistance. The glycolysis rate-limiting enzyme hexokinase II (HK II) is overexpressed in most tumor cells and significantly affects tumor development. This paper examines the structure of HK II and the specific biological factors that influence its role in tumor development, as well as the potential of HK II inhibitors in antitumor therapy. Furthermore, we identify and discuss the inhibitors of HK II that have been reported in the literature.